Higher priming doses enhance HIV-specific humoral but not cellular. responses in a randomized, double-blind phase Ib clinical trial of
|
|
- Leonard Flowers
- 5 years ago
- Views:
Transcription
1 Higher priming doses enhance HIV-specific humoral but not cellular responses in a randomized, double-blind phase Ib clinical trial of preventive HIV-1 vaccines Pierre-Alexandre Bart a,b, Yunda Huang c, Shelly T. Karuna c, Samuel Chappuis a, Julien Gaillard a, Nidhi Kochar c, Xiaoying Shen d, Mary A. Allen e, Song Ding b, John Hural c, Hua- Xin Liao d, Barton F. Haynes d, Barney S. Graham f, M. Juliana McElrath c,g,h,i, David C. Montefiori d, Georgia D. Tomaras d, Giuseppe Pantaleo a,j, Nicole Frahm c,g# and the NIAID HIV Vaccine Trials Network Service of Immunology and Allergy, University Hospital, Lausanne, Switzerland a ; EuroVacc Foundation, Lausanne, Switzerland b ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA c ; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA d ; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA e ; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health Bethesda, Maryland, USA f ; Departments of Global Health g, Laboratory Medicine h and Medicine i, University of Washington, Seattle, Washington, USA; Swiss Vaccine Research Institute, Lausanne, Switzerland j Running Head: Antibodies but not T cells benefit from stronger prime
2 Net Response (MFI - Blank) for clade AE gp /29 7.1% 23.1% 3/ % 1 Placebo NYVAC/Ad5 hi Ad5 lo /NYVAC Ad5 med /NYVAC Ad5 hi /NYVAC Supplemental Figure 1: Clade AE Env-specific binding antibody responses elicited in HVTN 078 two weeks after the final vaccination. IgG responses to clade AE Env gp120 (A244 gdneg/293f/mon) were measured as mean fluorescence intensity (MFI) of protein-labeled minus blank beads (see Methods).
3 0. 3.4% 1/ % 3/ % 7/ /14 60,000 IgG Titer (AUC) to clade B p Placebo NYVAC/Ad5 hi Ad5 lo /NYVAC Ad5 med /NYVAC Ad5 hi /NYVAC Supplemental Figure 2: Gag-specific binding antibody responses elicited in HVTN 078 two weeks after the final vaccination. IgG titer (AUC) to clade B Gag-p24.
4 Supplemental Figure 3. Env-specific binding IgG against linear peptides. Binding IgG in serum samples from 10 vaccinees that were among those with the highest neutralizing antibody responses were mapped using overlapping peptide (15-mers overlapping by 12) microarrays covering the entire gp160 of Consensus A, B, C, D, CRF01_AE, CRF02_AG and group M. All vaccinees within this subset had binding IgG responses to the V3 and C5 region of gp120; albeit at various levels. The C1 region of gp120 was also targeted by these vaccinees to different levels. No binding to linear gp41 peptides was detected (not shown). Shown here are three vaccinees that also had the strongest overall neutralizing antibody responses against multiple tier 1 viruses.
5 A B C Net Response (MFI - blank) for clade A IgA Net Response (MFI - blank) for clade C IgA Net Response (MFI - blank) for ConS IgA % 13/ % 19/ % 22/29 7.1% 14.3% 2/14 7.1% Placebo NYVAC/Ad5 hi Ad5 lo /NYVAC Ad5 med /NYVAC Ad5 hi /NYVAC Supplemental Figure 4: Env-specific IgA responses elicited in HVTN 078 two weeks after the final vaccination. IgA responses to A) consensus clade A gp140, B) consensus clade C gp140 and C) consensus group M gp140 were measured as mean fluorescence intensity (MFI) of protein-labeled minus blank beads (see Methods).
6 A 0/20 11% 3/ /15 62% 8/13 64% 9/14 29% 8 85% 79% 8/28 13/15 11/13 1 0/28 1/15 25% 7/28 73% 11/15 69% 9/13 64% 9/14 % CD8 T cells expressing IFN-γ and/or IL-2 % CD4 T cells expressing IFN-γ and/or IL-2 P Env Gag Nef Pol B 0/20 14% 4/29 7/15 46% 6/13 5 8/14 41% 4 54% 71% 12/29 6/15 7/13 1 0/29 1/15 45% 13/29 6 9/15 54% 7/13 64% 9/14 P Env Gag Nef Pol Supplemental Figure 5: T-cell responses elicited in HVTN 078. CD4+ (A) and CD8+ (B) T-cell responses to vaccine inserts were measured two weeks after the final vaccination by ICS and reported as % of CD4+ or CD8+ T cells producing IFN-γ and/or IL-2 for placebo recipients (P, combined for groups 1-4) and vaccinees in each treatment group (T1-T4). Positive responses are shown in red symbols, negative responses in blue. Box-whiskers represent positive responders only (see Methods). P: placebo, T1: NYVAC/Ad5 hi, T2: Ad5 lo /NYVAC, T3: Ad5 med /NYVAC, T4: Ad5 hi /NYVAC
HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial
The Journal of Clinical Investigation Clinical Medicine HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial Pierre-Alexandre Bart, 1,2,11 Yunda Huang, 3,11 Shelly T. Karuna,
More informationHVTN Laboratory Program: Immunogenicity and Research Assays
HVTN Laboratory Program: Immunogenicity and Research Assays Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali,
More informationSupplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood
Supplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood tree illustrating CRF01_AE gp120 protein sequence relationships between 107 Envs sampled in the RV144 trial
More informationTrial Objectives immunogenicity safety
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens requires 3 DNA injections. Long term Results of the EV03/ANRS Vac20 Phase I/II Trial. Yves Levy, Kim Ellefsen, Wolfgang Stöehr, Pierre-Alexandre
More informationHIV: RV 144 prime boost HIV vaccine efficacy study
HIV: RV 144 prime boost HIV vaccine efficacy study Nelson L. Michael, M.D., Ph.D Colonel, Medical Corps, U.S. Army Director US Military HIV Research Program (MHRP) Walter Reed Army Institute of Research
More informationHIV and Challenges of Vaccine Development
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV and Challenges of Vaccine Development Richard A. Koup, MD INTEREST
More informationHVTN P5 Vaccine Trials
HVTN P5 Vaccine Trials Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali, Rwanda 16-17 March 2015 HVTN Mission
More informationRecombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses
Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses Weimin Liu University of Alabama at Birmingham Introduction and Rationale Virus-like particles (VLPs)
More informationThe Kitchen Sink. Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona
The Kitchen Sink Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona The only important slide of my presentation. All efficacy trial in
More informationWhy are validated immunogenicity assays important for HIV vaccine development?
Why are validated immunogenicity assays important for HIV vaccine development? There is a need to compare immunogenicity of products in the pipeline, when similar or different in class when developed by
More informationNovel Vaccine Products for Planned Phase I Immunogenicity Studies in Infants
Office of AIDS Research Novel Vaccine Products for Planned Phase I Immunogenicity Studies in Infants L. Jean Patterson, PhD Office of AIDS Research, NIH February 7, 2017 Office of AIDS Research OAR Responsibilities
More informationModule 8: Evaluating Immune Correlates of Protection
Module 8: Evaluating Immune Correlates of Protection Instructors: Ivan Chan, Peter Gilbert, Paul T. Edlefsen, Ying Huang Session 7: RV144 Thai Trial Case Study (HIV Vaccine Efficacy Trial) Summer Institute
More informationInduction of Innate Immune Responses in HVTN 071: a Trial using the MRKAd5 gag/pol/nef Vaccine from the Step Study
Induction of Innate Immune Responses in HVTN 71: a Trial using the MRKAd5 gag/pol/nef Vaccine from the Step Study Erica Andersen-Nissen Vaccine and Infectious Disease Institute Fred Hutchinson Cancer Research
More informationModule 8: Introduction to Immune Correlates of Protection. Instructors: Ivan Chan, Peter Gilbert, Paul T. Edlefsen, Ying Huang
Module 8: Evaluating Immune Correlates of Protection Instructors: Ivan Chan, Peter Gilbert, Paul T. Edlefsen, Ying Huang Session 7: RV144 Thai Trial Case Study (HIV Vaccine Efficacy Trial) Summer Institute
More informationProgress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH. Division of Infectious Diseases Columbia University Medical Center
Progress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH Division of Infectious Diseases Columbia University Medical Center 1 Outline A short history of HIV vaccine design and development Describe
More information4/14/2016. HIV Vaccines and Immunoprotection: Where Are We? Learning Objectives. After attending this presentation, participants will be able to:
HIV Vaccines and Immunoprotection: Where Are We? Mark J. Mulligan, MD, FIDSA Distinguished Professor of Medicine Emory University School of Medicine Atlanta, Georgia FINAL: 04/01/16 Atlanta, Georgia: Friday,
More informationInnate and Cellular Immunology Control of Infection by Cell-mediated Immunity
Innate & adaptive Immunity Innate and Cellular Immunology Control of Infection by Cell-mediated Immunity Helen Horton PhD Seattle Biomedical Research Institute Depts of Global Health & Medicine, UW Cellular
More informationNIH Public Access Author Manuscript Nat Med. Author manuscript; available in PMC 2010 September 1.
NIH Public Access Author Manuscript Published in final edited form as: Nat Med. 2010 March ; 16(3): 319 323. doi:10.1038/nm.2089. Mosaic HIV-1 Vaccines Expand the Breadth and Depth of Cellular Immune Responses
More informationAlternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir
Alternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir Giuseppe Pantaleo, M.D. Professor of Medicine Head, Division of Immunology and Allergy Executive Director, Swiss Vaccine
More informationMosaic vaccines elicit CD8 + T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys
Mosaic vaccines elicit CD + T lymphocyte responses that fer enhanced immune coverage of diverse HIV strains in monkeys 21 Nature America, Inc. All rights reserved. Sampa Santra 1, Hua-Xin Liao 2, Ruijin
More informationHeterologous Tier 1 R5 SHIV-C Challenges: Correlates of Protection
Heterologous Tier 1 R5 SHIV-C Challenges: Correlates of Protection Enterprise Meeting: The Appropriate Use of Tiered Virus Panels when Assessing HIV-1 Vaccine-elicited Neutralizing Antibodies" July 7 th,
More informationStreamlining Heterologous DNA-Prime and NYVAC/Protein-Boost HIV Vaccine Regimens in
JVI Accepted Manuscript Posted Online 10 February 2016 J. Virol. doi:10.1128/jvi.03135-15 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 Streamlining Heterologous DNA-Prime
More informationHIV-1 acute infection: evidence for selection?
HIV-1 acute infection: evidence for selection? ROLLAND Morgane University of Washington Cohort & data S6 S5 T4 S4 T2 S2 T1 S1 S7 T3 DPS (days post symptoms) 3 (Fiebig I) 7 (Fiebig I) 13 (Fiebig V) 14 (Fiebig
More informationAIDSVaccine2010 Atlanta, Georgia Willy Bogers. NIH HIVRad Grant nr 5P01AI066287
HIV-1 envelope-cd4 receptor complexes elicit broad T- and B- cell immune responses as well as cross-reactive neutralizing antibodies in Rhesus macaques NIH HIVRad Grant nr 5P01AI066287 AIDSVaccine2010
More informationEmploying Improved Antigens Allows Streamlining of Heterologous DNA-Prime and NYVAC/Protein-Boost HIV Vaccine Regimens in Rhesus Macaques
Title Employing Improved Antigens Allows Streamlining of Heterologous DNA-Prime and NYVAC/Protein-Boost HIV Vaccine Regimens in Rhesus Macaques Running title: Improved HIV Antigens and Delivery Schedules
More informationProfessor Andrew McMichael
BHIVA AUTUMN CONFERENCE 2011 Including CHIVA Parallel Sessions Professor Andrew McMichael University of Oxford 17 18 November 2011, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationHIV Vaccine. Sunee Sirivichayakul, Ph.D. Faculty of Medicine Chulalongkorn University. August 22, 2014
HIV Vaccine Sunee Sirivichayakul, Ph.D. Faculty of Medicine Chulalongkorn University August 22, 2014 Immunity Natural immunity Active natural immunity e.g., infection Passive natural immunity e.g., trans-placental
More informationCombinatorial Vaccines for AIDS and other Infectious Diseases
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Combinatorial Vaccines for AIDS
More informationCurrent State of HIV Vaccine Development
Current State of HIV Vaccine Development Sandhya Vasan, MD US Military HIV Research Program Henry M. Jackson Foundation Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand AVAC HVAD
More informationQuestions and answers: HVTN 084 vaccine trial
1. What is the HVTN 084 trial? Questions and answers: HVTN 084 vaccine trial Version 2 Last updated December 2, 2010 HVTN 084 is the name of a clinical trial to test the safety of 2 experimental HIV vaccines.
More informationSafety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054)
Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054) Laurence Peiperl 1, Cecilia Morgan 2, Zoe Moodie 2,
More informationImmunogenicity of ALVAC HIV (vcp1521) and AIDSVAX B/E Prime Boost Vaccination in RV144, Thai Phase III HIV Vaccine Trial
Immunogenicity of ALVAC HIV (vcp1521) and AIDSVAX B/E Prime Boost Vaccination in RV144, Thai Phase III HIV Vaccine Trial M. de Souza, R. Trichavaroj, A. Schuetz, W. Chuenarom, Y. Phuang ngern, S. Jongrakthaitae,
More informationEvaluation of lead HIV-1 vaccine regimen in APPROACH:
Evaluation of lead HIV-1 vaccine regimen in : Phase 1/2a study testing heterologous prime boost regimens using mosaic Ad26 and MVA vectors combined with Env protein Hanneke Schuitemaker Martin Freeman,
More informationStart Date* Sites Description
HVTN 076 17 HVTN HVTN 084 100 HVTN HVTN 085 90 HVTN HVTN 096 96 HVTN IPPOX EuroVacc GSID USMHRP HVTN 098 94 HVTN Inovio clade B AIDSVAX B/E clade C NYVAC clade C PENNVAX-GP IL-12 adjuvant September-11
More informationSuperior Control of HIV-1 Replication by CD8+ T Cells Targeting Conserved Epitopes: Implications for HIV Vaccine Design
Superior Control of HIV-1 Replication by CD8+ T Cells Targeting Conserved Epitopes: Implications for HIV Vaccine Design Pratima Kunwar 1,7, Natalie Hawkins 2, Warren L. Dinges 1,3, Yi Liu 5, Erin E. Gabriel
More informationCurrent Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study
Note: I have added some clarifying comments to the slides -- please click on Comments under View to see them. Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a
More informationProfessor Jonathan Weber
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor Jonathan Weber Imperial College, London 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor
More informationThe Harvard community has made this article openly available. Please share how this access benefits you. Your story matters
Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1- Infected Individuals on Early Initiated Antiretroviral Therapy The Harvard community has made this article openly
More informationEfficacy Results from the Step Study
Efficacy Results from the Step Study (Merck V520 Protocol 023/HVTN 502) A Phase II Test-of-Concept Trial of the MRKAd5 HIV-1 Gag/Pol/Nef Trivalent Vaccine CROI February 5, 2008 Boston, MA Rationale for
More information* Corresponding author: Tel.: ; Fax:
JVI Accepted Manuscript Posted Online 8 February 2017 J. Virol. doi:10.1128/jvi.02182-16 Copyright 2017 American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
More informationTrial Collaborators Start Date* Sites Stage HVTN BMGF IPPOX EuroVacc GSID. HVTN DAIDS GSK Sanofi Jun 2017
Ongoing s:, In, Health/AESI Contact(s) 096/EV04 106 107 108 110 A phase 1 double blind placebo-controlled clinical trial to evaluate the safety and to compare the priming ability of NYVAC alone versus
More informationABSTRACT. n engl j med 369;22 nejm.org november 28,
The new england journal of medicine established in 1812 november 28, 2013 vol. 369 no. 22 Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Scott M. Hammer, M.D., Magdalena E. Sobieszczyk, M.D., M.P.H., Holly
More informationDNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 (OA 10.04)
DNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 (OA 10.04) Rashmi Jalah Human Retrovirus Pathogenesis Section, Vaccine Branch, CCR, National Cancer Institute
More informationTrials & Tribulations: on the way to cure: where do HIV Vaccines fit in? Glenda Gray SA HIV Clinicians Society Conference April, 2016
Trials & Tribulations: on the way to cure: where do HIV Vaccines fit in? Glenda Gray SA HIV Clinicians Society Conference 2016 13-16 April, 2016 Scope Rationale for an HIV vaccine RV144 study in Thailand
More informationQuestions and answers: HVTN 078 vaccine study
1. What is the HVTN 078 study? Version 2 Last updated March 11, 2011 HVTN 078 is the name of a clinical trial to test the safety and immune response of 2 experimental HIV vaccines. The experimental vaccines
More informationCorrelates of Immunity: RV144 - Lessons Learned
Correlates of Immunity: RV144 - Lessons Learned US Military HIV Research Program (MHRP) Nelson L. Michael, MD, PhD AIDS Vaccine 2010, Atlanta GA 01 October 2010 Outline RV 144 Correlates Discovery Towards
More informationDevelopment of a Universal T Cell Vaccine. Tomáš Hanke Weatherall Institute of Molecular Medicine University of Oxford United Kingdom
Development of a Universal T Cell Vaccine Tomáš Hanke Weatherall Institute of Molecular Medicine University of Oxford United Kingdom Development of HIV-1 vaccines Induction of cell-mediated responses Immunogens
More informationStart Date* Sites Description
076 17 083 180 084 100 085 90 098 94 Inovio rad35 clade A clade A rad clade B clade B PENNVAX-GP IL-12 adjuvant September-11 Seattle The study looks at the immune response of genital and rectal tissues
More informationNK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections
NK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections Amy Chung Dr. Ivan Stratov Prof. Stephen Kent ADCC process consists of Target cell QuickTime and a TIFF (Uncompressed) FcγR decompressor
More informationAdvancing HIV Vaccines into Efficacy studies. Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland
Advancing HIV Vaccines into Efficacy studies Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland What we need to end AIDS: controlling viremia New classes of Drugs Point of care viral load &
More informationPress conference abstracts Vaccine and Antibody Research Monday, 22 October 2018
Press conference abstracts Vaccine and Antibody Research Monday, 22 October 2018 OA02.05LB Vaccine-induced Gene Signature Correlates with Protection against Acquisition in Three Independent Vaccine Efficacy
More informationSupplementary information. Early development of broad neutralizing antibodies in HIV-1 infected infants
Supplementary information Early development of broad neutralizing antibodies in HIV-1 infected infants Leslie Goo, Vrasha Chohan, Ruth Nduati, Julie Overbaugh Supplementary Figure 1. Neutralization profile
More informationApplication of systems biology to identify predictors of HIV vaccine immunogenicity
Application of systems biology to identify predictors of HIV vaccine immunogenicity Daniel Zak 1, Erica Andersen-Nissen 2, Haesun Park 3, Scott Hansen 3, Karl Mullen 3, Kristi Hamilton 1, Kathleen Kennedy
More informationGenetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial
CORRECTION NOTICE Nat. Med. 17, 366 371 (2011) Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial Morgane Rolland, Sodsai Tovanabutra, Allan C decamp, Nicole Frahm, Peter
More informationOngoing HVTN Trials (Enrolling, In Follow-up, and in Long Term Follow-up)
Ongoing HVTN Trials (, In, and in ) HVTN 085 90 HVTN VRC rad5 multiclade 02/2012 Boston - Brigham; Chicago; Nashville; New York - NYBC; New York - NYBC - Bronx; Philadelphia; Rochester; San Francisco;
More informationHIV Vaccines: Basic Science
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV Vaccines: Basic Science Richard A. Koup, MD 6 th INTEREST Workshop
More informationHVTN RAMP Mentors
2016-2017 RAMP Scholars travel to an HVTN site and work closely with a mentor to conduct an HIV vaccine research project. We recommend that interested students e-mail Jenna Udren, RAMP Project Coordinator
More informationEMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV. (Summary of the recommendations from an Enterprise Working Group)
AIDS Vaccine 07, Seattle, August 20-23, 2007 EMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV (Summary of the recommendations from an Enterprise Working Group) The Working Group Reston, Virginia,
More informationGOVX-B11: A Clade B HIV Vaccine for the Developed World
GeoVax Labs, Inc. 19 Lake Park Drive Suite 3 Atlanta, GA 3 (678) 384-72 GOVX-B11: A Clade B HIV Vaccine for the Developed World Executive summary: GOVX-B11 is a Clade B HIV vaccine targeted for use in
More informationHIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case cohort analysis
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case cohort analysis M Juliana McElrath, Stephen C De Rosa, Zoe Moodie, Sheri Dubey, Lisa Kierstead, Holly Janes, Olivier D Defawe, Donald
More informationHeterologous Prime-Boost & Adjuvanted Env Protein HIV Vaccine Approaches
Heterologous Prime-Boost & Adjuvanted Env Protein HIV Vaccine Approaches Susan W. Barnett WHO-NIAID Meeting on HIV, Malaria, and TB Vaccines April 17-18, 2012 Rockville, MD Background & vision of HIV vaccine
More informationAn HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses
ARTICLE An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses The Journal of Experimental Medicine CORRESPONDENCE Giuseppe Pantaleo:
More informationOngoing HVTN Trials. Protocol N Trial Collaborators HVTN HVTN VRC DAIDS. Study Product(s)
HVTN 076 17 HVTN DNA multiclade rad5 multiclade 09/2011 The study looks at the immune response of genital and rectal tissues to injections of a DNA vaccine followed by a recombinant adenovirus serotype
More informationIncreasing Neutralisation resistance in HIV-1 Clade C over the course of the southern African Epidemic. Cecilia Rademeyer 26 October 2014
Increasing Neutralisation resistance in HIV-1 Clade C over the course of the southern African Epidemic. Cecilia Rademeyer 26 October 2014 HIV-1 Transmission and Antigenic Drift Individual Selection Transmission
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Barouch DH, Tomaka FL Wegmann F, et al. Evaluation
More informationVirus Panels for Assessing Vaccine-Elicited Neutralizing Antibodies
Virus Panels for Assessing Vaccine-Elicited Neutralizing Antibodies Michael Seaman, Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Harvard Medical School J. Virol.
More informationGeneration of Robust Antibody Responses to HIV-1 MPER Antigens in Mice Reconstituted with Cultured B cells
Generation of Robust Antibody Responses to HIV-1 MPER Antigens in Mice Reconstituted with Cultured B cells T. Matt Holl 1, Masayuki Kuraoka 1, Dongmei Liao 1, Laurent Verkoczy 2, M. Anthony Moody 2, Munir
More informationHIV An bodies Frequently Cross- React with Intes nal Microbiota An gens. Tony Moody Duke Human Vaccine Ins tute Duke University 8 April 2015
HIV An bodies Frequently Cross- React with Intes nal Microbiota An gens Tony Moody Duke Human Vaccine Ins tute Duke University 8 April 2015 Commensal Bacteria and the Immune System The intes ne is home
More informationShould There be Further Efficacy Testing of T-T cell Based Vaccines that do not Induce Broadly Neutralizing Antibodies?
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Should There be Further Efficacy
More informationPlanned Vaccine Trials to Follow-up on RV 144. Merlin Robb, MD Deputy Director for Clinical Research MHRP
Planned Vaccine Trials to Follow-up on RV 144 Merlin Robb, MD Deputy Director for Clinical Research MHRP Planned studies are mutually reinforcing and will amplify public health impact and regional relevance
More informationDNA Immunization for HIV Vaccine Development
University of Massachusetts Medical School escholarship@umms GSBS Student Publications Graduate School of Biomedical Sciences 2-25-2014 DNA Immunization for HIV Vaccine Development Yuxin Chen University
More informationCD40L-Adjuvanted DNA/MVA SIV Vaccine Enhances Protection. Against Neutralization Resistant Mucosal SIV Infection
JVI Accepted Manuscript Posted Online 4 February 2015 J. Virol. doi:10.1128/jvi.03527-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 CD40L-Adjuvanted DNA/MVA SIV Vaccine
More informationAntibody Dependent Cellular Cytotxic activity: Past and Future. Guido Ferrari, M.D. Duke University Medical Center
Antibody Dependent Cellular Cytotxic activity: Past and Future Guido Ferrari, M.D. Duke University Medical Center Mechanism of Antibody Dependent Cellular Cytotoxicity (ADCC) ADCC Effector Cells (NK, monocytes/macrophages,
More informationThird Env Manufacturing Workshop July 20 21, July 20, 2017 Mary Marovich, M.D. Director, Vaccine Research Program
Third Env Manufacturing Workshop July 20 21, 2017 July 20, 2017 Mary Marovich, M.D. Director, Vaccine Research Program Presentation Outline Importance and Impact of an HIV Vaccine DAIDS/VRP Programmatic
More informationALVAC -HIV and AIDSVAX B/E Prime-Boost HIV-1 Preventive Vaccine Regimen. Results of the Thai HIV Vaccine Trial, RV144
ALVAC -HIV and AIDSVAX B/E Prime-Boost HIV-1 Preventive Vaccine Regimen Results of the Thai HIV Vaccine Trial, RV144 SupachaiRerks-Ngarm, PunneePittisutthithum, SorachaiNitayaphan, JaranitKaewkungwal,
More informationA global approach to HIV-1 vaccine development
A global approach to HIV-1 vaccine development The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Published Version Accessed
More informationBispecific Fusion Antibodies. Exhibit 100% Breadth and Picomolar Potency. Craig Pace, PhD
The Aaron Diamond AIDS Research Center Affiliate of The Rockefeller University Bispecific Fusion Antibodies PG9 Ibalizumab & VRC Ibalizumab Exhibit % Breadth and Picomolar Potency Craig Pace, PhD AIDS
More informationRapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers
Rapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers Adam R. Hersperger Department of Microbiology University of Pennsylvania Evidence for
More informationPotential cross reactions between HIV 1 specific T cells and the microbiome. Andrew McMichael Suzanne Campion
Potential cross reactions between HIV 1 specific T cells and the microbiome Andrew McMichael Suzanne Campion Role of the Microbiome? T cell (and B cell) immune responses to HIV and Vaccines are influenced
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY INFORMATION Association of HLA-DRB1-restricted CD4 + T cell responses with HIV immune control Srinika Ranasinghe 1, Sam Cutler 1, Isaiah Davis 1, Richard Lu 2, Damien Z. Soghoian 1, Ying
More informationClone 3 Human Monoclonal Antibody Neutralizing Effect on HIV 2017
Science Improving Health Clone 3 Human Monoclonal Antibody Neutralizing Effect on HIV 2017 www.bioclonetics.com Invest at: www.wefunder.com/bioclonetics. Our video: https://youtu.be/spciismitxe Invest
More informationAGE DA. 8:00-8:30 Breakfast All. 8:30-8:40 Introductions All. 8:40-8:55 Mandate of the Enterprise Alan Bernstein
200 Park Ave. S. Suite 1501 New York, NY 10003 Ph: +1 866 966 4483 +1 212 461 3692 Fax: +1 212 780 0607 THE GLOBAL HIV VACCI E E TERPRISE (THE E TERPRISE) I AUGURAL MEETI G OF THE SCIE CE COMMITTEE WED
More informationHIV Antibody Characterization for Reservoir and Eradication Studies. Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks
HIV Antibody Characterization for Reservoir and Eradication Studies Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks Blood Systems Research Institute University of California San Francisco, CA
More informationHIV-1 Subtypes: An Overview. Anna Maria Geretti Royal Free Hospital
HIV-1 Subtypes: An Overview Anna Maria Geretti Royal Free Hospital Group M Subtypes A (1, 2, 3) B C D F (1, 2) G H J K Mechanisms of HIV-1 genetic diversification Point mutations RT error rate: ~1 per
More informationSommer. Memorial. Lectures
Getting to an HIV Vaccine: Necessity and Frustration Larry Corey, MD Principal Investigator, NIAID supported HIV Vaccine Trials Network (HVTN) Past President and Director, Fred Hutchinson Cancer Research
More informationNew Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS. Dublin, Ireland. June 24, AIDS Vaccines.
New Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS Dublin, Ireland June 24, 2004 AIDS Vaccines - An R&D Briefing This paper has been prepared by the International AIDS Vaccine
More informationNovel Heterologous Prime-Boost Vaccine Strategies for HIV. Dan Barouch April 18, 2012
Novel Heterologous Prime-Boost Vaccine Strategies for HIV Dan Barouch April 18, 2012 Desired Features of a Next Generation HIV-1 Vaccine Candidate The RV1 study suggests that an HIV-1 vaccine is possible
More informationHVTN HIV Diagnostics Program
HVTN HIV Diagnostics Program John Hural, Ph.D. Carissa Karg, MPH March 14, 2013 The HVTN is supported through a cooperative agreement with the National Institute of Allergy and Infectious Diseases 1 HIV
More informationDEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED
DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED Viv Peut Kent Laboratory, University of Melbourne, Australia WHY ENVELOPE? Env subject to both humoral and cellular immune responses Perhaps
More informationSupplementary Fig. 1: Ex vivo tetramer enrichment with anti-c-myc beads
Supplementary Fig. 1: Ex vivo tetramer enrichment with anti-c-myc beads Representative example of comparative ex vivo tetramer enrichment performed in three independent experiments with either conventional
More informationThe Rational Design of an AIDS Vaccine
Leading Edge Essay The Rational Design of an AIDS Vaccine Daniel C. Douek, 1 Peter D. Kwong, 1 and Gary J. Nabel 1, * 1 Vaccine Research Center, NIAID, National Institutes of Health, Room 4502, Building
More informationSubtype C ALVAC-HIV and bivalent subtype C gp120/mf59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial
Subtype C ALVAC-HIV and bivalent subtype C gp12/mf59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial Linda-Gail Bekker, Zoe Moodie, Nicole Grunenberg, Fatima Laher, Georgia
More informationT cell Vaccine Strategies for HIV, the Virus. With a Thousand Faces
JVI Accepts, published online ahead of print on 13 May 2009 J. Virol. doi:10.1128/jvi.00114-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationReceived 15 November 2000; revised 6 February 2001; electronically published
1343 Safety and Immunogenicity of a Canarypox-Vectored Human Immunodeficiency Virus Type 1 Vaccine with or without gp120: A Phase 2 Study in Higher- and Lower-Risk Volunteers Robert B. Belshe, 1 Cladd
More informationQuestions and answers: HVTN 110 vaccine study
1. What is a vaccine study? A vaccine teaches the body to prevent a particular infection or fight a disease. In order to develop a vaccine, researchers need to test it in people. A vaccine study tests
More informationDenny 1, Barton Haynes 1, Norman L. Letvin 2, Guido Ferrari 1, David C. Montefiori 1, Georgia D.
JVI Accepts, published online ahead of print on 6 July 2011 J. Virol. doi:10.1128/jvi.05174-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationSupporting Information
Supporting Information Sui et al..7/pnas.997 Pre-CLP CM9 LA9 SL Tat# Pol Vif % Tetramer + CD + CD + Vac+IL- +IL- Vac Fig. S. Frequencies of six different CD + CD + Mamu-A*-tetramer + cells were measured
More informationSelection on the Human Immunodeficiency Virus Type 1 Proteome following Primary Infection
JOURNAL OF VIROLOGY, Oct. 2006, p. 9519 9529 Vol. 80, No. 19 0022-538X/06/$08.00 0 doi:10.1128/jvi.00575-06 Copyright 2006, American Society for Microbiology. All Rights Reserved. Selection on the Human
More informationAdvancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates
Vaccines 2014, 2, 15-35; doi:10.3390/vaccines2010015 Review OPEN ACCESS vaccines ISSN 2076-393X www.mdpi.com/journal/vaccines Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune
More informationTricks in HIV s bag to counter vaginal or rectal microbicides
Tricks in HIV s bag to counter vaginal or rectal microbicides Florian Hladik, MD, PhD University of Washington Fred Hutchinson Cancer Research Center Seattle Contribution of the various HIV invasion routes
More information